1. ALLA AKTIER
  2. NYHETER
  3. 2CUREX

2cureX

Nyheter 2cureX Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).

2cureX Management will present status on the published goals for 2023 and additional important achievements.

The Q&A session will be hosted by Stokk.io and will allow you to submit questions from today and during the live event. You can sign up via the following link: Q&A webcast for Q3 2023. Stokk.io will act as moderator during the session.

The Q&A event will be livestreamed on the same link. The event is recorded and transcribed and made available for all investors afterwards on our website. 

The full quarterly report will be published on November 23 and a video commentary will be held on the same day (hosted by Infront Direkt).

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB

Attachments

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).

Datum 2023-10-03, kl 09:15
Källa MFN
Bifogade filer
2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).